Research

Overview

Selected publications:
1. Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach.
Noaiseh G, Baer AN. Best Pract Res Clin Rheumatol. 2020 Feb;34(1):101475. doi: 10.1016/j.berh.2019.101475. Epub 2020 Jan 28.PMID: 32005417

2. Unique Sjögren's syndrome patient subsets defined by molecular features.
James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW.
Rheumatology (Oxford). 2020 Apr 1;59(4):860-868. doi: 10.1093/rheumatology/kez335.PMID: 31497844

3. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.
St Clair EW, Baer AN, Wei C, Noaiseh G, Parke A, Coca A, Utset TO, Genovese MC, Wallace DJ, McNamara J, Boyle K, Keyes-Elstein L, Browning JL, Franchimont N, Smith K, Guthridge JM, Sanz I, James JA; Autoimmunity Centers of Excellence.
Arthritis Rheumatol. 2018 Sep;70(9):1470-1480. doi: 10.1002/art.40513. Epub 2018 Jul 18.PMID: 29604186

4. Comparison of the discontinuation rates and side-effect profiles of pilocarpine and cevimeline for xerostomia in primary Sjögren's syndrome.
Noaiseh G, Baker JF, Vivino FB.
Clin Exp Rheumatol. 2014 Jul-Aug;32(4):575-7. Epub 2014 Jul 23.PMID: 25065774